Erratum: 'Assessing generalisability by location in trial-based cost-effectiveness analysis: The use of multilevel models' (Health Economics (2004) DOI: 10.1002/hec.914);Assessing generalisability by location in trial-based cost-effectiveness analysis: The use of multilevel models

Health Economics

Volumn 14, Issue 5, 2005, Pages 471-485

  Manca, Andrea ^a   Rice, Nigel ^a   Sculpher, Mark J ^a   Briggs, Andrew H ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Generalisability; Multilevel modelling; Multinational and multicentre RCTs; Trial based cost effectiveness analysis

Indexed keywords

ANALYTICAL ERROR; ARTICLE; CLINICAL PRACTICE; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MATHEMATICAL COMPUTING; OUTCOMES RESEARCH; PRIORITY JOURNAL; STOCHASTIC MODEL;

EID: 19444381224     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.957     Document Type: Erratum

References (42)

1. Chaudahry MA, Sterns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomised trial. Stat Med 1996; 15: 1447-1458.
2. Willan AR, O'Brien B. Confidence intervals for cost-effectiveness ratios: an application of Fiellers' theorem. Health Econ 1996; 5: 297-305.
3. Briggs AH, Mooney CZ, Wonderling DE. Contructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. Stat Med 1999; 18: 3245-3262.
4. Van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ 1994; 3: 309-319.
5. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779-789.
6. Sloan F, Feldman RD, Steinwald AB. Effects of teaching on hospital costs. J Health Econ 1983; 2: 1-28.
7. Drummond MF, Bloom BS, Carrin G et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992; 8: 671-682.
8. O'Brien BJ. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. Am J Managed Care 1997; 3: S33-S39.
9. Sculpher MJ, Poole L, Cleland J et al. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the assessment of treatment with Lisinopril and survival (ATLAS) study. Eur J Heart Fail 2000; 2: 447-454.
10. Scott WC, Cooper BC, Scott HM. Pharmacoeconomics evaluation of Roxithromycin versus Amoxycillin/Clavulanic acid in a community-acquired lower respiratory tract infection study. Infection 1995; 23: S21-S24.
11. Rajan R, Gafni A, Levine M, Hirsh J, Gent M. Very low-dose Warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J Clin Oncol 1995; 13: 42-46.
12. Dasbach EJ, Rich MW, Segal R et al. The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure. Cardiology 1999; 91: 189-194.
13. Nord E, Wisloff F, Hjorth M, Westin J. Cost-utility analysis of Melphalan plus Prednisone with or without Interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial. Pharmacoeconomics 1997; 12: 89-103.
14. Schulman KA, Buxton M, Glick H et al. Results of the economic evaluation of the FIRST study. A multinational prospective economic evaluation. Int J Technol Asses Health Care 1996; 12: 698-713.
15. Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999; 42: 1293-1301.
16. Raikou M, Briggs A, Gray A, McGuire A. Centre-specific or average unit costs in multi-centre studies. Some theory and simulation. Health Econ 2000; 9: 191-198.
17. Willke RJ, Glick HA, Polsky D, Schulman KA. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7: 481-493.
18. Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med 2003; 22: 1955-1976.
19. Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decision Making 1998; 18: S68-S80.
20. Hoch JS, Briggs AH, Willan A. Something old, something new, something borrowed, something BLUE: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002; 11: 415-430.
21. DiPetre TA, Forristal JD. Multilevel models: methods and substance. Ann Rev Sociol 1994; 20: 331-357.
22. Goldstein H, Rasbash J, Yang M et al. A multi level analysis of school examination results. Oxford Rev Educ 1993; 19: 425-433.
23. Aitkin M, Longford N. Statistical modelling issues in school effectiveness studies. J R Stat Soc, Ser A 1986; 149: 1-43.
24. Brown H, Prescott R. Applied Mixed Models in Medicine. Wiley: Chichester, 1998.
25. Cardoso AR. Wage differentials across firms: an application of multilevel modelling. J Appl Econ 2000; 15: 343-354.
26. Rice N, Leyland A. Multilevel models: applications to health data. J Health Services Res and Policy 1996; 1: 154-164.
27. Rice N, Jones AM. Multilevel models and health economics. Health Econ 1997; 6: 561-575.
28. Briggs AH. Handling uncertainty in economic evaluation and presenting the results. In Economic Evaluation in Health Care. Merging Theory with Practice, Drummond MF, McGuire A (eds). Oxford University Press: Oxford, 2001.
29. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996; 5: 513-524.
30. Tambour M, Zethraeus NMJ. A note on confidence intervals in cost-effectiveness analysis. Int J Technol Assess Health Care 1998; 14: 467-471.
31. Briggs AH. A Bayesian approach to stochastic cost effectiveness analysis. Health Econ 1999; 8: 257-262.
32. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. Br Med J 1998; 317: 720-726.
33. Roberts C. The implication of variation in outcome between health care professionals for the design and analysis of randomised controlled trials. Stat Med 1999; 18: 2605-2615.
34. Moerbeek M, Breukelen GJP, Berger MPF. A comparison between traditional methods and multilevel regression for the analysis of multicenter intervention studies. J Clin Epidemiol 2003; 56: 341-350.
35. Snijders TAB, Bosker RJ. Multilevel Analysis. An Introduction to Basic and Advanced Multilevel Modeling. Sage Publications: London, 1999.
36. Sculpher M, Manca A, Abbott J, Fountain J, Mason S, Garry R. The cost-effectiveness of laparoscopic-assisted hysterectomy in comparison with standard hysterectomy: The EVALUATE Trial. Br Med J 2004; 328(7432): 134-139.
37. Garry R, Hawe J, Abbott J et al. The EVALUATE study: randomised trials comparing laparoscopic with abdominal and vaginal hysterectomy. Br Med J 2004; 328(7432): 129-133.
38. Kind P. The EuroQoL instrument: an index of health-related quality of life. In Quality of Life and Pharmacoeconomics in Clinical Trials, Spilker B (ed.). Lippincott-Raven: Philadelphia, 1996.
39. Kind P, Hardman GSM. UK Population Norms for EQ-5D. Discussion Paper. Centre for Health Economics, University of York: York, 1999. Report No.: 172.
40. Rasbash J, Browne W, Goldstein H et al. A User's Guide to MLwiN Version 2.1. Institute of Education, University of London: London, 2000.
41. Barcikowski RS. Statistical power with group mean as the unit of analysis. J Educ Stat 1981; 6: 267-285.
42. Baltagi BH. Econometric Analysis of Panel Data. Wiley: Chichester, 2001.